One important function of endocannabinoids and related lipid mediators in mammalian central nervous system is modulation of pain. Evidence obtained during the last decade shows that altered levels of these compounds in brain accompany decreases in pain sensitivity. Such changes, if sexually dimorphic, could account for sex-differences in pain and differences that occur during different phases of the hormonal cycle in females. To examine this possibility, we measured the levels of the pain-modulatory lipids anandamide, 2-arachidonoyl glycerol, N-arachidonoyl glycine, Narachidonoyl gamma amino butyric acid, and Narachidonoyl dopamine in seven different brain areas (pituitary, hypothalamus, thalamus, striatum, midbrain, hippocampus, and cerebellum) in male rats, and in female rats at five different points in the estrous cycle. Cycle differences: The cerebellum did not demonstrate a change in endocannabinoid production across the estrous cycle, whereas all other areas tested showed significant differences in at least one of the compounds measured. These changes in levels occurred predominately within the 36 hour time period surrounding ovulation and behavioral estrus. Sex differences: Differences between males and females were measured as either estrous cycleindependent (all estrous cycles combined) or cycledependent (comparisons of males to each estrous cycle). In cycle-independent analyses, small sex differences were observed in the pituitary, hypothalamus, cerebellum, and striatum, whereas no differences were observed in the thalamus, midbrain, and hippocampus. In cycledependent analyses, the hypothalamus and pituitary showed largest sex differences followed by the striatum, midbrain, and hippocampus, whereas no sex differences were measured in thalamus and cerebellum. These data provide a basis for investigations into how differences in sex and hormonal status play a role in mechanisms regulating endocannabinoid production and pain.
Introduction
Endogenous cannabinoids are involved in a myriad of physiological processes including immune function, feeding regulation, vascular tone, memory, mood, reproduction, and pain (for reviews see 29, 31; 34, 35; 44, 45, 46) . Sex differences in the cannabinoid signalling system have been reported, these being limited mainly to examinations of sex-and cycle-related differences in the efficacy of the exogenous cannabinoid delta-9 tetrahydrocannabinol (THC, reviewed by 6). The antinoceptive effects of THC were significantly greater in female rats versus male rats in a model of acute peripheral pain (39) . Prenatal THC exposure produced a sex-dependent effect on proenkephalin mRNA levels in several brain regions in which females had significantly higher expression than males (28) . Also, the cannabinoid receptor agonist CP55 940 produced greater antinociception in peri-pubertal female rats compared to male rats (34) . Sex and hormonal cycle differences in brain cannabinoid receptor densities and affinities were also observed (32) .
Elucidating the mechanism of action of endogenous cannabinoids on pain and other systems has centered on understanding the endogenous ligands arachidonoyl ethanolamine (AEA; 9) and 2-arachidonoyl glycerol (2-AG; 25; 38) in relation to the known cannabinoid receptors, CB1 (7) and CB2 (19) . Cannabinoid receptors have been localized in the central nervous system, which contains primarily CB1 (14; 27, 40, but see 42) , and the immune system, which contains primarily CB2 (14) . Other endogenous compounds that are structurally similar to AEA or 2AG, and are active in classical cannabinoid tetrad tests (hypothermia, catalepsy, locomotion, and nociception; 22) , or bind to cannabinoid receptors are becoming recognized as members of the family of cannabimimetic lipid mediators, more simply known as endocannabinoids. As outlined in a recent review (5) , many of these compounds are likely involved in the neurophysiology of pain. For instance, N-arachidonoyl glycine (NAGly) and N-arachidonoyl gamma amino butyric acid (NAGABA) have been shown to be antinociceptive and anti-inflammatory (16) and N-arachidonoyl dopamine (NADA) has been shown to cause hyperalgesia and bind to CB1 and TRPV1 receptors (17) .
The study of endocannabinoid formation in the midbrain has implications for understanding the neurophysiology of pain. An increase in release of anandamide in the periaqueductal gray (PAG) was shown to be associated with CB1-mediated analgesia induced by stimulation of the dorsal and lateral PAG (46) . More recently, anandamide and 2-AG production in the dorsal midbrain was shown to be associated with stress-induced analgesia (15) . These studies demonstrated that changes in endocannabinoid levels lead to concomitant changes in pain sensitivity. Therefore, changes in the formation of endocannabinoids in the brain as a result of sex or hormonal cycle may account for some of the sex and hormonal cycle differences observed in various pain conditions.
Pain is defined as a sensory, emotional, and motivational experience. Therefore, it is unsurprising that activation of nociceptors recruits multiple areas of the brain involved in these experiences. Even though the midbrain has been identified as a key component in the descending modulation of pain, this extremely complex perception likely does not follow one specific pathway. As a first step toward examining the role of the endogenous cannabinoid system in sex differences in pain, we measured the levels of five endocannabinoids in seven brain regions in male rats and in female rats at five time points in the hormonal cycle using liquid chromatography/tandem mass spectrometry (LC/MS/MS). The five time points in the 4-day cycling female were early metestrus, early diestrus, early proestrus, late proestrus/early behavioral estrus, and late behavioral estrus. These times were chosen to examine the times of most dynamic endocrine and behavioral changes as outlined in a recent article stating the strategies and methods for research on the study of sex and cycle differences (2) .
Experimental Methods

Materials
[ 2 H 8 ]-Anandamide, and 2-arachidonylglycerol were purchased from Cayman Chemical, Ann Arbor,MI. Narachidonylglycine, N-arachidonyl gamaaminobutyric acid, and N-arachidonyldopamine were purchased from Biomol, Plymouth Meeting, PA. High performance liquid chromatography (HPLC) grade water, methanol, and acetonitrile were purchased from VWR international, Plainview, NY. HPLC grade acetic acid and ammonium acetate were purchased from Sigma-Aldrich.
Animals
Age matched and littermate female Sprague-Dawley rats at five points of estrous cycle (n=7 per group) and male SpragueDawley rats (n=7), 10-14 weeks old, females weighing 250-300g, males 400-450g were maintained on a 12:12-h light/dark cycle (7:00 light-19:00 dark) with food and water ad libitum. Determination of the stage of the estrous cycle was assessed by daily vaginal smears, which were obtained during the first two hours of the light phase on each day for at least 2 weeks prior to tissue collection. Additionally, male rats were handled in a manner similar to that of females during vaginal smears to control for any stress effects Tissue was collected only in rats for which vaginal smears indicated that the rat exhibited 3 consecutive regular 4-day cycles. Rats with more or less than a fourday cycle were not used in this study.
Tissue collection
Animals were euthanized by decapitation at 10:00h for the light cycle points and 22:00h for the dark cycle time point. On any given test day, rats at different points in the estrous cycle and males were randomly selected (e.g. 1 in metestrus, 1 in diestrus, 1 in proestrus, and 1 male) for tissue collection. Brains were dissected with forceps on an ice-cold metal dissection plate into the following regions: hypothalamus, pituitary, striatum, thalamus, hippocampus, midbrain, and cerebellum. Each of the seven tissues was placed in pre-weighed microfuge tubes, then weighed and flash frozen in liquid nitrogen to be stored at -80°C until used for lipid extraction and analysis. Each dissection was performed by the same experimenter to ensure continuity. The entire procedure took ~10 minutes, which is significantly less than the amount of time required for post-mortem generation of 2-AG and anandamide (20) .
Compound Extraction from brain tissue
All tissues from the same brain area were processed on the same day. Tissues were removed from the -80ºC freezer and twenty volumes of 1:1 mixture of cold methanol and acetonitrile were added to each tissue and kept on ice. The compounds being measured are Analytes were extracted from the supernatant using C18 solid phase extraction columns (100mg for pituitary and hypothalamus, 500mg for striatum, thalamus, hippocampus, midbrain, and cerebellum; Varian, Harbor City, CA). Each 100 mg column was conditioned with 2.5 ml methanol and 2 ml water, whereas, 500 mg columns were conditioned with 5.0 ml methanol and 2.5 ml water followed by loading of the water/supernatant solution. Columns were then washed with 2 ml water and 1.5 ml 55% methanol. Compounds were eluted with 1.75 ml methanol. Each elution was vortexed at maximum speed for 1 minute prior to mass spectrometric analysis.
LC/MS/MS analysis and quantification
Samples were analyzed by LC/MS/MS. Rapid separation was obtained using 10 µl injections of analyte (Agilent 1100 series autosampler, Palo Alto, CA) onto a Zorbax eclipse XDB 2.1X50 mm reversed phase column. Gradient elution (200 µl/min) was formed under pressure on a pair of Shimadzu 10AdVP pumps (Columbia, Maryland). Mass spectrometric analysis was performed with an Applied Biosystems/MDS Sciex (Foster City, CA) API3000 triple quadrupole mass spectrometer using electrospray ionization. Levels of each compound were analyzed by multiple reactions monitoring (MRM) on the LC/MS/MS system. In MRM mode, detection of each compound is based on fragmentation of the precursor ion [ 
Data Analysis
The data were analyzed as male values compared to all female values combined (cycleindependent sex differences), male values compared to individual estrous cycle time points (cycle-dependent sex differences), and comparisons among all estrous cycle time points. Each of these comparisons was statistically analyzed using SPSS software. Statistical differences were determined using ANOVA with post-hoc Fisher's LSD using a 95% confidence interval for the mean. Data are presented as means ± SE of the means where p 0.05 was considered statistically significant.
Results
Calibration curves based upon synthetic standards were used in combination with isotope dilution methods to calculate the amount of analyte in each sample. Figure 1 illustrates a chromatogram of a 1 fmol NADA standard, a chromatogram of striatum extract using the NADA MRM method from a female in night proestrus, and a combined chromatogram of both. The matching retention time and the isolation of both the precursor ion and a specific fragment ion by the MRM scan provide high confidence that the material being measured in the tissue extract is the compound of interest. Table 1 illustrates the average weights of the dissected brain regions illustrating the relatively low degree of variability among the groups. Because sex and estrous stage differences were found in the wet weights of the tissues (Table  1) , all compounds were analyzed as moles per gram tissue.
In all tissues examined, 2-AG was found in approximately 1000 times higher levels than any of the other compounds. The levels of NAGABA were below our detection limit in pituitary, and the levels of NADA were below our detection limit in all brain regions except striatum. However, in a subset of samples the eluent was dried-down, pooled, and reconstituted (male rats only). In these samples, NADA was also found in picomoles per gram in hippocampus, and femtomoles per gram in cerebellum, thalamus, brainstem, and midbrain.
Cycle-independent sex differences
To examine overall sex differences in brain endocannabinoid levels, data from each of the five estrous cycle time points were combined and compared to males. Table 2 illustrates these values. Levels of 2-AG were found to be significantly lower in males in hypothalamus and pituitary, yet significantly higher in cerebellum. NAGABA levels in the striatum were significantly lower in males. 
Pituitary
Estrous cycle differences
The levels of 2-AG measured in pituitary were significantly higher in proestrus (P) compared to NP (night proestrus/early behavioral estrus) and E (morning/late behavioral estrus) ( Fig. 2A) , whereas, AEA levels were significantly higher in P only compared to metestrus (M; Fig. 2B ). Conversely, levels of NAGly in the pituitary were significantly lower in NP compared to all estrous stages (Fig. 2C) .
Cycle-dependent Sex differences
Levels of 2-AG in males were significantly lower in pituitary compared to females in all stages of estrous (Fig. 2 A) . Pituitary levels of NAGly in males were significantly lower compared to females in diestrus (D), P, E, and M (Fig. 2C) . No cycledependent sex differences in levels of pituitary AEA were observed (Fig. 2B) . Hypothalamus Estrous cycle differences AEA levels were significantly higher in D compared to all other stages of the cycle (Fig.  3B) . Levels of 2-AG in hypothalamus were significantly higher in D compared to P and M (Fig. 3A) . Similarly, levels of NAGABA were significantly higher in D compared to M (Fig.  3D) . Conversely, NAGly levels were significantly lower in E compared to D, P, and NP (Fig. 3C) .
Levels of 2-AG in males were significantly lower in hypothalamus compared to females in D, NP, and E (Fig. 3A) . Similarly, levels of AEA and NAGABA in males were significantly lower in hypothalamus compared to females in D (Fig. 3B) . No cycle-dependent sex differences were measurable in levels of NAGly (Fig. 3C) .
Thalamus Estrous cycle differences
Levels of 2-AG in thalamus were significantly higher in NP compared to P (Fig.  4A) . No estrous cycle differences were measurable for AEA, NAGly, or NAGABA. (Fig. 4B, C, D) .
Cycle-dependent Sex differences
No cycle-dependent sex differences in the levels of 2-AG, AEA, NAGly, or NAGABA were measurable (Fig. 4A, B, C, D) . 
Cerebellum
Estrous cycle differences
No estrous cycle differences in 2-AG, AEA, NAGly, or NAGABA were observed ( Fig  .5A, B, C, D) .
Cycle-dependent Sex differences
No cycle-dependent sex differences in 2-AG, AEA, NAGly, or NAGABA were observed (Fig .5A, B, C, D) .
Striatum
Estrous cycle differences
The levels of NADA were significantly lower in P compared to D (Fig. 6E) . No estrous cycle differences in 2-AG, AEA, NAGly, or NAGABA were measurable (Fig. 6A, B, C, D) .
Cycle-dependent Sex differences
The levels of NAGly in males were significantly lower in striatum compared to females in D and NP (Fig. 6C) . Likewise, NAGABA levels in males were significantly lower compared to females in M, D, NP, and E (Fig. 6D) . No cycle-dependent sex differences in 2-AG, AEA, or NADA were measurable (Fig. 6A, B, E) .
Hippocampus Estrous cycle differences
Levels of 2-AG and NAGABA in hippocampus were significantly lower in P (Fig. 7A, D) . Similarly, AEA levels were significantly lower in P compared to NP and E (Fig. 7B) and NAGly levels in hippocampus were significantly lower in P compared to NP, E, and M (Fig. 7C) .
Cycle-dependent Sex differences
Levels of AEA in males were significantly higher in hippocampus compared to females in P (Fig. 7B ). There were no measurable sex differences in 2-AG, NAGly, or NAGABA (Fig .7A, C, D) .
Midbrain Estrous cycle differences
Levels of 2-AG in midbrain were significantly higher in NP compared to P, E, M, and D (Fig. 8A) . Similarly, levels of AEA in midbrain were significantly higher in NP compared to P, E, and M (Fig. 8B ). There were no measurable differences in NAGly and NAGABA across the estrous cycle (Fig. 8C, D) .
Cycle-dependent Sex differences
2-AG levels in midbrain in males were significantly lower than females in NP (Fig.  8A) . Likewise, AEA levels were significantly lower in males compared to females in NP. There were no measurable cycle-dependent differences in NAGly and NAGABA levels between males and females (Fig. 8C, D) . Tables 3 and 4 summarize the differences in the five endocannabinoid levels measured here in all seven brain areas as a function of estrous cycle and cycle-dependent sex differences respectively.
Discussion
The levels of five endocannabinoids in brain vary as a function of sex and hormonal cycle (M=metestrus; D=diestrus, P=proestrus, NP=night proestrus/behavioral estrus, and E=estrus). Hormonal cycle differences in endocannabinoid production center primarily on the period surrounding ovulation and receptivity (early proestrus, late proestrus/early behavioral estrus, and late behavioral estrus). In examining the cycle-independent comparisons of male versus female levels of endogenous cannabinoids we observed few differences, with the predominate finding being the different levels of 2-AG. However, when these comparisons were made in a cycle-dependent manner, an array of differences were observed The levels of endocannabinoids measured here are equivalent to those observed in previous studies that measured nanomolar amounts of 2-AG (4) and picomolar amounts of anandamide (4, 10, and 37), NAGly (16) , and NADA (17) . In those studies that correlated behavioral changes to changes in midbrain anandamide and 2-AG production the change in production levels were between 20 and 40 percent (17, 45) . Significant differences in production levels of endocannabinoids observed here were between 16 and 53 percent. Given that these changes were measured in relatively large regional dissections of tissue, this suggests a functional relevance of the regulation of these compounds by changes in the hormonal milieu.
The possible relationships between the hormonal and endocannabinoid systems and their synergistic roles in brain neurophysiology have yet to be fully elucidated. While there are some data addressing potential hormonal regulatory roles for anandamide and 2-AG production, there are no data on hormonal relationships with NAGly, NAGABA, and NADA. Therefore, our discussion on how these data may relate to our current understanding of the field will primarily focus on anandamide and 2-AG. The implications for these data for further investigations into the mechanisms underlying sex differences in pain are multifaceted and will likely vary depending on the brain area of study.
Pituitary
In the anterior pituitary, CB1 receptor density is higher in males than in females during diestrus (13) . Here, we found that the levels of endocannabinoids are significantly higher in proestrus compared to other points in the cycle (approximately 24 hours later). It is difficult to adequately compare the two results because in our study the two lobes of the pituitary were combined. Both findings do, however, suggest a neuroendocrine regulatory role for the pituitary endocannabinoid system. Although the pituitary has a myriad of functions, one of its neuroendocrine products involved in stress and pain is prolactin (1, 18, 21, 30) . AEA delivered to the cerebral ventricles was shown to significantly decrease prolactin release in male rats and initiate a significant increase in prolactin release in estrogen-primed ovariectomized females (36) . While the mechanisms of prolactin and its influence on pain are not fully understood (12, 18, 26, 30) , the regulatory interactions between prolactin, endocannabinoids, and hormonal milieu may prove to be important in understanding the mechanisms of pain associated with prolactin release in certain pain disorders.
Hypothalamus
de Fonseca et al. (32) showed that the densities of cannabinoid receptors in the hypothalamus were the highest in diestrus decreasing through the cycle and becoming significantly lower in estrus. A complementary pattern was observed in levels of AEA, 2-AG, and NAGABA (i.e. the levels were significantly higher in diestrus compared to other stages of the estrous cycle). Additionally, we show here that there is a significant overall sex difference in the level of hypothalamic 2-AG, whereas, de Fonseca and colleagues showed no sex difference in receptor density (32) . However, that study did not compare males to females at different stages of the cycle so we can not compare and contrast those data to the current findings. While one may postulate many functional outcomes consequent to these differences, one avenue to explore is the etiology of headache. A recent review of the neurobiology of primary headaches targets the hypothalamus as one of the key brain areas involved (9) . Given that there are significant sex differences in primary headaches (3), this may be a fruitful area of exploration to understand the regulatory factors among these neurophysiological systems. Hippocampus Changes in dendritic spine type and density as a function of sex and hormonal status have been demonstrated by many researchers (24, 48) . These changes in spine density occur at the same time as the changes in endocannabinoid levels that we observed here. Additionally, endocannabinoids have been implicated in a myriad of hippocampal cellular events including those associated with pain processing (43; for rev see 11) . The data here provide a basis to examine the role of changes in hippocampal dendritic spines associated with sex and hormonal differences, endocannabinoids, and the interactions of these systems in the context of pain.
Midbrain
The production of the endocannabinoids anandamide and 2-AG in the midbrain in response to noxious stimuli and stress demonstrated a direct relationship between endocannabinoid production and suppression of pain (46; 15) . The significant increases in the levels of both anandamide and 2-AG in the midbrain during night proestrus/behavioral estrus may be related to the behavioral changes that occur during that time period. MartinezGomez et al (23) , showed significant diurnal variations with longer tail-flick latencies at the beginning of the dark phase (the time of sampling in this study). This effect was most pronounced in diestrus and proestrus suggesting a change in physiology with the dark phase that was cycle dependent. In addition, de Fonseca et al. (32) showed an overall sex difference in cannabinoid receptor density in which males had higher levels in the midbrain, yet they did not observe a significant cycle difference in the three time points they measured (which did not include late proestrus). They did observe, however, a significant increase in receptor density in ovariectomized females that had progesterone replacement. Night proestrus/behavioral estrus is the time point in the cycle in which progesterone is the highest. The high levels of AEA and 2-AG at a time in the cycle when progesterone is elevated suggests a hormonal regulatory role for the midbrain endocannabinoid system.
The changes in midbrain AEA and 2-AG observed in the current study could, however, be due to a diurnal change in midbrain AEA and 2-AG. One group using gas chromatography/mass spectrometry (GC/MS) showed dramatic diurnal differences in 2-AG and AEA in male rat brain (42) , finding that 2-AG increased 2-4 fold while AEA decreased 2-4 fold in all areas of the brain during the dark phase. While we did measure increases in 2-AG during the dark phase, we did not measure any decreases in AEA production levels in this study. These differences are likely due to significant differences in experimental conditions between these studies including but not limited to the differences between GC/MS and LC/MS/MS, their use of pooled samples verses our use of individual samples, and sex differences.
Conclusions
This study was undertaken to provide a baseline from which to develop hypotheses on sex differences and pain and the results shown here have provided that framework. The knowledge that endocannabinoid levels are regulated differently between the sexes and that the majority of these differences are dependent on changes across the estrous cycle sets the stage for future experiments aimed at elucidating the relationships between endocannabinoids, hormonal milieu, and pain.
